Home R&D/Anti-IL-17B mAbs>
Latest News
See all news


Anti-IL-17B mAbs

The IL-17 family of pro-inflammatory cytokines is involved in the progression of several human diseases. Within the IL-17 family, our group focuses on the role of the IL-17B cytokine and its receptor and cancer and inflammatory diseases.


IL-17B and its receptor, IL-17RB, are upregulated in cancer and correlate to poor prognosis. In vivo, the neutralization of the IL-17B cytokine dramatically impacts tumor progression and survival in several immunocompetent mouse models by a dual mechanism of action on both tumor cells and the tumor microenvironment. First, disruption of IL-17B affects the cancer stem cells, leading to decreased tumorigenesis, reduced ability to seed distant tumors and improved response to therapies such as chemotherapy or EGFR inhibitors. Second, the presence of IL-17B also affects the immune antitumor response.


Our team has generated and characterized several monoclonal antibodies targeting IL-17B and has established the in vivo POC of their antitumor activity. 


See all events